Brown Rudnick partner and a Practice Group Leader in the Firm's Global Life Sciences Practice Group Adam Schoen authored “Cell and Gene Therapies Are Driving Investment Opportunities.” The article was published in Cell & Gene, a product of Life Science Connect. In the article, Schoen discussed immune therapies and gene-based therapies related to the brain, and how these therapies present growing opportunities for investors in the life sciences space.
For more than 20 years, Schoen has worked in the life sciences industry. He advises life sciences and medical device funds, companies, and academic institutions. Prior to launching his legal career, Schoen was a scientist of analytical chemistry for ArQule Inc., a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals Inc.
Cell & Gene is a media resource providing news to professionals involved in the development and commercialization of cell and gene therapies. Cell & Gene’s editorial scope spans the entire product lifecycle from basic research to commercialization.
Read the complete article here.
/Passle/62189924f636e915f48daeda/SearchServiceImages/2025-10-20-20-51-52-599-68f6a0e866329001bbee3af4.jpg)
/Passle/62189924f636e915f48daeda/SearchServiceImages/2025-10-14-20-16-01-982-68eeaf81a56f2d11bcac094b.jpg)
/Passle/62189924f636e915f48daeda/SearchServiceImages/2025-10-13-20-16-59-488-68ed5e3b8c37e725183e5d13.jpg)
/Passle/62189924f636e915f48daeda/SearchServiceImages/2025-09-21-13-44-32-308-68d00140df36028526d42051.jpg)